Diurnal update: adrenal insufficiency treatment for paediatric patients

Diurnal have announced that the European Commission has granted a paediatric use marketing authorisation (PUMA) for Alkindi® (development programme name: Infacort®; hydrocortisone granules in capsules for opening) as replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to <18 years old), following the positive opinion issued by the European Medicines Agency (EMA) in December 2017.

For full details visit their website


Medicine Gyfzv4qd